Evaluating the safety of Clausena harmandiana root-bark powder (Song Fa) capsules in healthy volunteers: A phase 1 clinical trial
Main Article Content
Keywords
safety, Clausena harmandiana, Song Fa, healthy volunteers, phase I clinical trial, 7-methoxyheptaphylline
Abstract
Background: Cancer is the leading cause of death worldwide. Chemotherapy is an important clinical treatment for cancer. However, the limitation of chemotherapy is its adverse effects on normal cells. Currently, the research focus is on the development of drugs and chemical compounds that have fewer side effects on normal cells. Extracts of Clausena harmandiana (C. harmandiana; Song Fa) root-bark have anticancer effects and is non-toxic to normal cells. Moreover, 7-methoxyheptaphylline, found in the root-bark of Song Fa, has been shown to inhibit the metastasis of breast cancer to the lungs in BALB/c mice. In this Phase I clinical trial, we aimed to investigate the safety of Song Fa in healthy volunteers. Objectives: To evaluate the safety and determine the adverse effects of C. harmandiana root-bark powder (Song Fa) capsules in healthy volunteers. Methods: An open-label, single-arm trial was conducted at the Ubon Ratchathani University Hospital, Thailand, between December 2022 and February 2023. The study enrolled 10 healthy male and 10 healthy female volunteers. Each volunteer orally ingested capsules of C. harmandiana root-bark extract (450 mg per capsule) once daily before breakfast for 14 days, and attended follow-up appointments after 1, 7, and 14 days. Physical examinations, signs and symptoms, hematology, and blood chemistry (e.g., liver function test, lipid profile, renal function test, and electrolytes) were assessed for screening (Day 0), at the beginning of the trial (Day 1), and on Days 7 and 14. After finishing the trial on Day 14, all volunteers were invited to participate in a follow-up session. To evaluate the safety of the C. harmandiana root-bark powder (Song Fa) capsules, each volunteer engaged in a phone interview on Day 30. The results were assessed against the normal range and baseline using repeated-measures ANOVA statistics. Results: At an oral dose of 450 mg/day, C. harmandiana root-bark powder (Song Fa) capsules did not result in serious adverse effects among the healthy volunteers. Participant physical examination results were all within normal ranges. All laboratory tests including hematology, liver and renal functions, lipid profiles, blood sugar levels, and serum electrolytes remained within normal limits. Measurements were taken the day before drug administration and at 1, 7, and 14 days post-dosing. Using repeated measures ANOVA to compare pre-treatment values at a 95% confidence interval, no significant differences were noted, except in fasting blood sugar levels, which showed a deviation from baseline (p < 0.001). However, these levels were within the normal ranges. Conclusion: The study results confirmed that C. harmandiana root-bark powder (Song Fa) capsules are safe in healthy volunteers. Physical health assessment and laboratory results did not differ from normal values.
References
2. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029-30. https://doi.org/10.1002/cncr.33587
3. Loftus LV, Amend SR, Pienta KJ. Interplay between Cell Death and Cell Proliferation Reveals New Strategies for Cancer Therapy. Int J Mol Sci. 2022;23(9):4723. https://doi.org/10.3390/ijms23094723
4. Boonyarat C, Yenjai C, Vajragupta O, Waiwut P. Heptaphylline induces apoptosis in human colon adenocarcinoma cells through bid and Akt/NF-κB (p65) pathways. Asian Pac J Cancer Prev. 2014;15(23):10483-7. https://doi.org/10.7314/apjcp.2014.15.23.10483
5. Nillert N, Boonyarat C, Welbat JU, Bunreungthong K, Puthongking P, Pannangrong W. Clausena Harmandiana root extract attenuated cognitive impairments via reducing amyloid accumulation and neuroinflammation in Aβ1-42-induced rats. BMC Complement Med Ther. 2022;22(1):108. https://doi.org/10.1186/s12906-022-03591-4
6. Boonyarat C, Yenjai C, Monthakantirat O, et al. Multifunctionality of Clausena harmandiana extract and its active constituents against Alzheimer’s disease. Curr Issues Mol Biol. 2022;44(8):3681-94. https://doi.org/10.3390/cimb44080252
7. Jantakoon P, Tadtong S, Puthongking P. Neuritogenic and antioxidant activities of nordentatin from Clausena harmandiana. J Asian Assoc Sch Pharm. 2012;1:180-6.
8. Wangboonskul J, Prawan A, Takthaisong P, et al. Analgesic, anti-inflammatory, antipyretic activities and acute toxicity of the ethanolic extract of Clausena harmandiana Pierre in animals. J Asian Assoc Sch Pharm. 2012;1:159-69.
9. Thongthoom T, Songsiang U, Phaosiri C, Yenjai C. Biological activity of chemical constituents from Clausena harmandiana. Arch Pharm Res. 2010;33(5):675-80. https://doi.org/10.1007/s12272-010-0505-x
10. Boonyarat C, Tantiwatcharakunthon M, Takomthong P, et al. Neuroprotective and anticancer effects of 7‑Methoxyheptaphylline via the TAK1 pathway. Oncol Rep. 2023;49(1):15. https://doi.org/10.3892/or.2022.8452
11. Huang L, Feng ZL, Wang YT, Lin LG. Anticancer carbazole alkaloids and coumarins from Clausena plants: A review. Chin J Nat Med. 2017;15(12):881-8. https://doi.org/10.1016/s1875-5364(18)30003-7
12. Boonyarat C, Yenjai C, Reubroycharoen P, et al. 7-Methoxyheptaphylline enhances TRAIL-induced apoptosis of colorectal adenocarcinoma cell via JNK-mediated DR5 expression. Biol Pharm Bull. 2023;46(8):1072-8. https://doi.org/10.1248/bpb.
b23-00036
13. Klungsupya P, Muangman T, Thisayakorn K, et al. Anti-anxiety activity, acute toxicity and cytotoxic property of extract of Clausena harmandiana (Pierre) leaves. Isan J Pharm Sci. 2015;10:199-206.
14. The Song Fa Research Group. Drugs development from Clausena harmandiana and natural compounds of Clausena harmandiana 2023. Ubon Ratchathani: Ubon Ratchathani University, Thailand;2021.
15. Bae JW, Kim DH, Lee WW, Kim HY, Son CG. Characterizing the human equivalent dose of herbal medicines in animal toxicity studies. J Ethnopharmacol. 2015;162:1-6. https://doi.org/10.1016/j.jep.2014.12.023
16. Food and Drug Administration. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. https://www.fda.gov/media/72309/download. Published 2005. Accessed 20 May,
2023.
17. Chavalittumrong P, Sriwanthana B, Pattamadilok S, Rattanajarasroj S, Chantapet P, Warachit P. Safety of Derris scandens hydroalcoholic extract in healthy volunteers. J Thai Traditional Altern Med. 2005;3:17-26.
18. Athipornchai A, Kumpang R, Semsri S. Potential Biological Activities of Clausena Essential Oils for the Treatment of Diabetes. J Oleo Sci. 2021;70(11):1669-76. https://doi.org/10.5650/jos.ess19294
19. Lal M, Begum T, Gogoi R, et al. Anethole rich Clausena heptaphylla (Roxb.) Wight & Arn., essential oil pharmacology and genotoxic efficiencies. Sci Rep. 2022;12(1):9978. https://doi.org/10.1038/s41598-022-13511-8
20. Quan NV, Anh H, Lam VQ, et al. Anti-diabetes, anti-gout, and anti-leukemia properties of essential oils from natural spices Clausena indica, Zanthoxylum rhetsa, and Michelia tonkinensis. Molecules. 2022;27(3):774. https://doi.org/10.3390/molecules27030774
21. Arbab IA, Abdul AB, Aspollah M, et al. A review of traditional uses, phytochemical and pharmacological aspects of selected members of Clausena genus (Rutaceae). Journal of Medicinal Plants Research. 2012;6(38):5107-5118.
22. Fakruddin M, Mannan KSB, Mazumdar RM, Afroz H. Antibacterial, antifungal and antioxidant activities of the ethanol extract of the stem bark of Clausena heptaphylla. BMC Complement Med Ther. 2012;12:1-9. https://doi.org/10.1186/1472-6882-12-232
23. García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules. 2020;10(11):1575. https://doi.
org/10.3390/biom10111575